PharmacoVig_BOS said:The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks…
I disagree that the ladder is purely tolerability. The maintenance and regain data cluster at the top doses, so a ladder abandoned halfway leaves you outside the evidence base for the part that matters most — keeping it off.
LondonLisa said:Four dose steps in, holding each one the full four weeks, and I am trying to work out whether the interval is a pharmacological requirement or a…
Dose escalation anxiety for titration: I was terrified to move from 0.5mg to 1.0mg based on horror stories in this forum. But my actual experience? Slightly more appetite suppression, zero additional side effects.
Remember that the people posting about terrible side effects are a biased sample. Most people titrate up without drama — they just don't post about it because it's uneventful.
DebRD_ATL said:I disagree that the ladder is purely tolerability.
Adding the part of the answer the thread has not reached. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from MeganSA_TX — and this may be the naive question:
What the trials actually did with participants who could not tolerate a step, because that is the situation I am in and the protocol summaries skip it?
Closing the loop on my own question.
Closing this out: I held the step for six weeks rather than four and it settled without a dose change. The interval was the answer, not the dose.